Why are upper tract urothelial carcinoma two different diseases?

por Szarvas, Tibor, Módos, Orsolya, Horváth, András, Nyirády, Péter
Publicado 2016

Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data

por Reis, Henning, Krafft, Ulrich, Niedworok, Christian, Módos, Orsolya, Herold, Thomas, Behrendt, Mark, Al-Ahmadie, Hikmat, Hadaschik, Boris, Nyirady, Peter, Szarvas, Tibor
Publicado 2018

Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients

por Olah, Csilla, Tschirdewahn, Stephan, Hoffmann, Michèle J., Krafft, Ulrich, Hadaschik, Boris, Nyirady, Peter, Szendröi, Attila, Módos, Orsolya, Csizmarik, Anita, Kovalszky, Ilona, Reis, Henning, Szarvas, Tibor
Publicado 2020

High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy

por Krafft, Ulrich, Olah, Csilla, Reis, Henning, Kesch, Claudia, Darr, Christopher, Grünwald, Viktor, Tschirdewahn, Stephan, Hadaschik, Boris, Horvath, Orsolya, Kenessey, Istvan, Nyirady, Peter, Varadi, Melinda, Modos, Orsolya, Csizmarik, Anita, Szarvas, Tibor
Publicado 2021

Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study

por Váradi, Melinda, Horváth, Orsolya, Módos, Orsolya, Fazekas, Tamás, Grunewald, Camilla M., Niegisch, Günter, Krafft, Ulrich, Grünwald, Viktor, Hadaschik, Boris, Olah, Csilla, Maráz, Anikó, Furka, Andrea, Szűcs, Miklós, Nyirády, Péter, Szarvas, Tibor
Publicado 2023

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance

por Módos, Orsolya, Reis, Henning, Niedworok, Christian, Rübben, Herbert, Szendröi, Attila, Marcell A., Szász, Tímár, József, Baghy, Kornélia, Kovalszky, Ilona, Golabek, Tomasz, Chlosta, Piotr, Okon, Krzysztof, Peyronnet, Benoit, Mathieu, Romain, Shariat, Shahrokh F., Hollósi, Péter, Nyirády, Péter, Szarvas, Tibor
Publicado 2016

Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer

por Keresztes, Dávid, Csizmarik, Anita, Nagy, Nikolett, Módos, Orsolya, Fazekas, Tamás, Bracht, Thilo, Sitek, Barbara, Witzke, Kathrin, Puhr, Martin, Sevcenco, Sabina, Kramer, Gero, Shariat, Shahrokh, Küronya, Zsófia, Takács, László, Tornyi, Ilona, Lázár, József, Hadaschik, Boris, Lászik, András, Szűcs, Miklós, Nyirády, Péter, Szarvas, Tibor
Publicado 2021

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas

por Varadi, Melinda, Nagy, Nikolett, Reis, Henning, Hadaschik, Boris, Niedworok, Christian, Modos, Orsolya, Szendroi, Attila, Ablat, Jason, Black, Peter C., Keresztes, David, Csizmarik, Anita, Olah, Csilla, Gaisa, Nadine T., Kiss, Andras, Timar, Jozsef, Toth, Erika, Csernak, Erzsebet, Gerstner, Arpad, Mittal, Vinay, Karkampouna, Sofia, Kruithof de Julio, Marianna, Gyorffy, Balazs, Bedics, Gabor, Rink, Michael, Fisch, Margit, Nyirady, Peter, Szarvas, Tibor
Publicado 2023

Prevalence of APC and PTEN Alterations in Urachal Cancer

por Nagy, Nikolett, Reis, Henning, Hadaschik, Boris, Niedworok, Christian, Módos, Orsolya, Szendrői, Attila, Bíró, Krisztina, Hager, Thomas, Herold, Thomas, Ablat, Jason, Black, Peter C., Okon, Krzysztof, Tolkach, Yuri, Csizmarik, Anita, Oláh, Csilla, Keresztes, David, Bremmer, Felix, Gaisa, Nadine T., Kriegsmann, Joerg, Kovalszky, Ilona, Kiss, András, Tímár, József, Szász, Marcell A., Rink, Michael, Fisch, Margit, Nyirády, Péter, Szarvas, Tibor
Publicado 2020